Publication
Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Portugal
| dc.contributor.author | Gouveia, M | |
| dc.contributor.author | Fiorentino, F | |
| dc.contributor.author | Jesus, G | |
| dc.contributor.author | Costa, J | |
| dc.contributor.author | Borges, M | |
| dc.date.accessioned | 2019-04-08T09:36:13Z | |
| dc.date.available | 2019-04-08T09:36:13Z | |
| dc.date.issued | 2017 | |
| dc.description.abstract | Pneumococcal infections are the leading cause of vaccine-preventable death in children. In June 2015, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in the Portuguese Immunization Program. We evaluated the cost-effectiveness of children vaccinated with PCV13 versus no vaccination for preventing pneumococcal diseases. | pt_PT |
| dc.description.version | info:eu-repo/semantics/publishedVersion | pt_PT |
| dc.identifier.citation | Pediatr Infect Dis J. 2017 Aug;36(8):782-787 | pt_PT |
| dc.identifier.doi | 10.1097/INF.0000000000001587 | pt_PT |
| dc.identifier.uri | http://hdl.handle.net/10400.17/3234 | |
| dc.language.iso | eng | pt_PT |
| dc.publisher | Wolters Kluwer | pt_PT |
| dc.subject | Child, Preschool | pt_PT |
| dc.subject | Cost-Benefit Analysis | pt_PT |
| dc.subject | Humans | pt_PT |
| dc.subject | Incidence | pt_PT |
| dc.subject | Infant | pt_PT |
| dc.subject | Immunization | pt_PT |
| dc.subject | Models, Immunological | pt_PT |
| dc.subject | Pneumococcal Infections | pt_PT |
| dc.subject | Pneumococcal Vaccines | pt_PT |
| dc.subject | CHLC FAR | pt_PT |
| dc.title | Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine in Children in Portugal | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 787 | pt_PT |
| oaire.citation.issue | 8 | pt_PT |
| oaire.citation.startPage | 782 | pt_PT |
| oaire.citation.volume | 36 | pt_PT |
| rcaap.rights | openAccess | pt_PT |
| rcaap.type | article | pt_PT |